share_log

Barrington Research Maintains Outperform on Lifecore Biomedical, Lowers Price Target to $8

Barrington Research Maintains Outperform on Lifecore Biomedical, Lowers Price Target to $8

巴灵顿研究维持Lifecore Biomedicare的跑赢大盘,将目标价下调至8美元
Benzinga ·  2023/03/21 09:05

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and lowers the price target from $10 to $8.

巴灵顿研究分析师迈克尔·佩图斯基维持Lifecore Biomedical(纳斯达克股票代码:LFCR)跑赢大盘,并将目标股价从10美元下调至8美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发